Abstract: The present invention provides a non-crosslinked acrylic polymer and a non-crosslinked anionic exchange resin consisting of polyacryloyloxyethyl-N,N-dimethylbenzyl ammonium salt.
Abstract: This invention relates to pharmacologically-active polymeric compounds; to substrates, such as implantable medical devices formed thereof or coated therewith; and to methods of using said compounds or said substrates for providing pharmacological agents released in response to in vivo activation at a desired location in a mammal. The polymeric material has a backbone comprising a pharmacologically-active fragment covalently linked through at least two functional groups within the backbone, wherein the backbone comprises, preferably, polyamide, polyurethane and/or polyurea linkages with, optionally, polyester, polycarbonate, polyether and/or polyvinyl linkages. The preferred pharmacological compounds are fluoroquinolines, particularly, ciprofloxacin. The pharmacologically-active compounds provide in vivo enhanced long term anti-inflammatory, anti-bacterial, anti-microbial and/or anti-fungal activity.
Abstract: The invention concerns a complex comprising a cell adhesion protein or a fragment thereof and Cu ions. The cell adhesion protein may be, for example, fibronectin and the Cu ions may be, for example, Cu.sup.2+ ions. The Cu ions stabilize the cell adhesion protein and the complex may be used to promote wound healing.
Abstract: A delivery system for controlled administration of a dentin-hypersensitivity-ameliorating composition to targeted areas is described. In particular, a bio-compatible delivery vehicle is described which contains unreacted, reactive materials dispersed therein. These materials form a dentin-hypersensitivity-ameliorating composition when reacted. Furthermore, these materials are separately encapsulated within protective encapsulating matrices to prevent the reaction thereof until delivery of the materials to a dentinal surface.
Abstract: The invention relates to an odoriferous composition containing a dispersion of microcapsules consisting of at least one surfactant with an odoriferous ingredient encapsulated therein.A method for preparing said compositions and their use for giving off a scent for repelling animals are also disclosed.
Abstract: The present invention further provides a substantially non-aqueous agricultural pesticide concentrate formulation of a non-ionic surfactant and a amphipathic graft copolymer composition in admixture with a water-insoluble organic agricultural pesticide which concentrate formulation can be easily diluted with water to form non-settling, freeze-thaw stable formulations.The present invention further provides methods for the use of water-diluted agricultural pesticide concentrate formulations of the above non-ionic surfactant concentrate formulations in the kill and control of agricultural pest.
Type:
Grant
Filed:
January 21, 1997
Date of Patent:
August 4, 1998
Assignee:
The Dow Chemical Company
Inventors:
Craig J. Bott, Dale M. Pickelman, Ritchie A. Wessling
Abstract: A pharmaceutical suspension formulation comprising 0.1 to 40% by weight ##STR1## as the active ingredient; 0.1 to 40% by weight Transcutol; 0.1-99% by weight starch; 0-40% by weight polyethylene glycol, NaOH and water,wherein the mole equivalents of NaOH per mole equivalent of active ingredient is from 0.5 to 1.5 is particularly useful for filling hard gelatin capsules.
Abstract: 1,3,5-Triazine-2,4,6-tris-alkylaminocarboxylic acid derivatives of the general formula (I): 1,3,5-triazine-2,4,6-tris?NH--(CH.sub.2).sub.n --CO--O--R.sup.1 ! are employed as biocidal or biostatic agents in aqueous systems, in particular in cooling lubricants. Fungicides, for example pyrithione or derivatives thereof and/or N-alkyl-diazenium dioxide salts, can be added to the aqueous systems. 0.05 to 0.40% by weight of the 1,3,5-triazine-2,4,6-alkylaminocarboxylic acid derivatives and 0.0001 to 0.2% by weight of fungicides are sufficient to maintain the biocidal or biostatic actions.
Abstract: Device capable of being used in combination with a restraining or ornamental collar or with any other support for animals, intended to make possible the controlled and optically continuous and complete release of chemical substances, including medicaments, for more or less lengthy, continuous or noncontinuous, periods and process for producing the said device. The device comprises a polymeric matrix enclosing at least one active substance capable of being released towards an appropriate area of an animal. The device is composed of at least one tubular component of any cross-section, containing at least one layer of flexible polymeric matrix containing at least one active substance, the length of the said tubular component can be regulated to adjust the daily dose of the active substance to the weight of the animal and the ratio of the external surface area of said tubular component to the thickness of its' wall is as great as possible to obtain linear removal of the active substance.
Type:
Grant
Filed:
January 19, 1996
Date of Patent:
July 7, 1998
Assignee:
Laboratoires Virbac
Inventors:
Christian Karst, Thierry Gozlan, Guy Derrieu, Luc Castelli
Abstract: Described is a hydrophilic adhesive base material comprising a hydrophilic crosslinked polymer obtained by polymerizing (A) (a) a glucosyloxyalkyl (meth)acrylate, (b) an alkyl (meth)acrylate and/or a hydroxyalkyl (meth)acrylate and (c) a polyfunctional monomer; and (B) polyvinyl alcohol. The hydrophilic adhesive base material according to the present invention is free from lowering in the water content and has excellent mechanical strength and adhesion to the skin so that it is useful as adhesive layers in plasters, various medical pads and also medicament-impregnated dermatologic medicines.
Abstract: Autologous fibrinogen and chitosan containing hemostatic adhesive agents having strong hemostatic properties when applied to a bleeding wound or vessel. Fibrinogen is isolated and purified using ammonium sulphate precipitation in slow incremental portions.
Type:
Grant
Filed:
April 23, 1996
Date of Patent:
June 30, 1998
Assignee:
The Regents of the University of California
Inventors:
Kent C. Cochrum, Harold R. Parker, Maggie M. C. Chiu
Abstract: Sustained release oral solid dosage forms comprising agglomerated particles of a therapeutically active medicament in amorphous form, a gelling agent, an ionizable gel strength enhancing agent and an inert diluent, as well as processes for preparing and using the same are disclosed. The sustained release oral solid dosage forms are useful in the treatment of hypertension in human patients.
Abstract: An orally administrable sustained-release dosage form includes particles of an active pharmaceutical ingredient which is coated with a polymeric material that is water-insoluble, but water-permeable and water-swellable, so that the sustained-release dosage form provides controlled release which is independent of certain variable physiological factors such as pH. In accordance with one aspect of the invention, the active pharmaceutical ingredient is acetaminophen and the coated acetaminophen particles are combined with uncoated acetaminophen particles to provide a combination immediate-release/sustained-release dosage form.
Abstract: Disclosed are novel polymers derivatized with at least one --NO.sub.X group per 1200 atomic mass unit of the polymer. X is one or two. In one embodiment, the polymer is an S-nitrosylated polymer and is prepared by reacting a polythiolated polymer with a nitrosylating agent under conditions suitable for nitrosylating free thiol groups. The polymers of the present invention can be used to coat medical devices to deliver nitric oxide in vivo to treatment sites.
Type:
Grant
Filed:
August 2, 1996
Date of Patent:
June 23, 1998
Assignee:
Duke University Medical Center
Inventors:
Jonathan S. Stamler, Eric J. Toone, Richard S. Stack
Abstract: Hydrophobically-modified bioadhesive polyelectrolytes containing a bioadhesive polyelectrolyte and a hydrophobic component are disclosed. Also disclosed are polyelectrolyte-agent compositions wherein the hydrophobically-modified bioadhesive polyelectrolyte is loaded with a pharmaceutically, cosmetically, or prophylactically acceptable agent. Suitable agents have hydrophobic and/or ionic character, and include drugs. The polyelectrolyte-agent compositions may be formulated for administration by topical, oral and/or systemic routes. Methods of administering such agents to an animal are also disclosed, and include administration of an effective amount of the polyelectrolyte-agent composition to the animal.
Type:
Grant
Filed:
August 16, 1995
Date of Patent:
June 23, 1998
Assignees:
University of Washington, Green Cross Corporation
Inventors:
Tadaaki Inoue, Guohua Chen, Allan S. Hoffman
Abstract: Nanoparticles are prepared by dissolving a poly(ethylene oxide) and/or poly(propylene oxide) polylactic copolymer in an organic solvent followed by formation of nanoparticles by mixing the solution containing the polymer with an aqueous solution and by precipitation, without using an additional colloidal protective agent or by microfluidization and solvent evaporation. Nanoparticles prepared by this method are disclosed.
Type:
Grant
Filed:
June 5, 1995
Date of Patent:
June 16, 1998
Assignee:
Rhone-Poulenc Rorer S.A.
Inventors:
Gilles Spenleuhauer, Didier Bazile, Michel Veillard, Christian Prud'Homme, Jean-Paul Michalon
Abstract: Wound implant materials are described comprising a plurality of bioabsorbable microspheres bound together by a bioabsorbable matrix, such as in a freeze-dried collagen matrix. The microspheres preferably comprise over 30% of the volume of the material, and preferably have diameters of 10 .mu.m to 1500 .mu.m. The microspheres and/or the matrix preferably comprise a polylactic/polyglycolic copolymer, collagen, cross-linked collagen, hyaluronic acid, cross-linked hyaluronic acid, an alginate or a cellulose derivative. The resulting implants are stronger and more slowly resorbed than conventional collagen sponge implants. Better control over the porosity of the implant is achieved.
Abstract: A method for simultaneously treating osteoporosis and hypertension in the same individual by the administration of pharmaceutically acceptable alkalinizing potassium salts, such as potassium bicarbonate, preferably in the form of a dietary supplement.
Type:
Grant
Filed:
June 5, 1995
Date of Patent:
June 16, 1998
Assignee:
The Regents of the University of California
Inventors:
R. Curtis Morris, Jr., Anthony Sebastian
Abstract: A method and composition for cleansing a wound comprising irrigating the wound with a surfactant, an antiseptic, and a preservative mixed in an aqueous solution having minimal cytotoxicity, and thereby cleansing the wound with minimal scarring.
Abstract: The present invention relates to leave on, skin care compositions, comprising: (a) from about 0.1% to about 30% of a sunscreen active, (b) from about 0.5% to about 20% of a hydrophobic, structuring agent, (c) from about 0.2% to about 10% of a hydrophilic surfactant, (d) from about 0.1% to about 5% of a thickening agent, and (e) water. These compositions are useful for providing protection to human skin from the harmful effects of ultraviolet radiation.